Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1111/ajt.16783 http://scihub22266oqcxt.onion/10.1111/ajt.16783 34358400!ä!34358400 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Am+J+Transplant 2022 ; 22 (1): 289-293 Nephropedia Template TP {{tp|p=34358400|t=2022. Diffuse C4d staining of peritubular capillaries in renal allograft following bamlanivimab therapy |pdf=|usr=}}{{34358400}} gab.com Text Diffuse C4d staining of peritubular capillaries in renal allograft following bamlanivimab therapy JO: Am J Transplant http://www.kidney.de/pget.php?&tw=1&pmid=34358400 #FOAvip Neutralizing monoclonal antibodies such as bamlanivimab emerged as promising agents in treating kidney transplant recipients with COVID-19. However, the impact of bamlanivimab on kidney allograft histology remains unknown. We report a case of a kidney transplant recipient who received bamlanivimab for COVID-19 with subsequent histologic findings of diffuse peritubular capillary C4d staining. A 33-year-old man with end-stage kidney disease secondary to hypertension who received an ABO compatible kidney from a living donor, presented for his 4-month protocol visit. He was diagnosed with COVID-19 44 days prior to his visit and had received bamlanivimab with an uneventful recovery. His 4-month surveillance biopsy showed diffuse C4d staining of the peritubular capillaries without other features of antibody-mediated rejection (ABMR). Donor-specific antibodies were negative on repeat evaluations. ABMR gene expression panel was negative. His creatinine was stable at 1.3 mg/dl, without albuminuria. Given the temporal relationship between bamlanivimab and our observations of diffuse C4d staining of the peritubular capillaries, we hypothesize that bamlanivimab might bind to angiotensin-converting enzyme 2, resulting in classical complement pathway and C4d deposition. We elected to closely monitor kidney function which has been stable at 6 months after the biopsy. In conclusion, diffuse C4d may present following bamlanivimab administration without any evidence of ABMR. Twit Text FOAVip Diffuse C4d staining of peritubular capillaries in renal allograft following bamlanivimab therapy ????Am J Transplant http://www.kidney.de/pget.php?&tw=1&pmid=34358400 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34358400 #FOAvip English Wikipedia <ref>{{Cite pmid|34358400}}</ref> Diffuse C4d staining of peritubular capillaries in renal allograft following bamlanivimab therapy #MMPMID34358400 Klomjit N; El Ters M; Adam BA; Sampathkumar P; Razonable RR; Taler SJ; Taner T; Alexander MP Am J Transplant 2022[Jan]; 22 (1): 289-293 PMID34358400show ga Neutralizing monoclonal antibodies such as bamlanivimab emerged as promising agents in treating kidney transplant recipients with COVID-19. However, the impact of bamlanivimab on kidney allograft histology remains unknown. We report a case of a kidney transplant recipient who received bamlanivimab for COVID-19 with subsequent histologic findings of diffuse peritubular capillary C4d staining. A 33-year-old man with end-stage kidney disease secondary to hypertension who received an ABO compatible kidney from a living donor, presented for his 4-month protocol visit. He was diagnosed with COVID-19 44 days prior to his visit and had received bamlanivimab with an uneventful recovery. His 4-month surveillance biopsy showed diffuse C4d staining of the peritubular capillaries without other features of antibody-mediated rejection (ABMR). Donor-specific antibodies were negative on repeat evaluations. ABMR gene expression panel was negative. His creatinine was stable at 1.3 mg/dl, without albuminuria. Given the temporal relationship between bamlanivimab and our observations of diffuse C4d staining of the peritubular capillaries, we hypothesize that bamlanivimab might bind to angiotensin-converting enzyme 2, resulting in classical complement pathway and C4d deposition. We elected to closely monitor kidney function which has been stable at 6 months after the biopsy. In conclusion, diffuse C4d may present following bamlanivimab administration without any evidence of ABMR. |*COVID-19[MESH] |*Kidney Transplantation/adverse effects[MESH] |Adult[MESH] |Allografts[MESH] |Antibodies, Monoclonal, Humanized[MESH] |Antibodies, Neutralizing[MESH] |Biopsy[MESH] |Capillaries[MESH] |Complement C4b[MESH] |Graft Rejection/drug therapy/etiology[MESH] |Humans[MESH] |Kidney[MESH] |Male[MESH] |Peptide Fragments[MESH] |SARS-CoV-2[MESH]Diffuse C4d staining of peritubular capillaries in renal allograft fol(epmc).pdf DeepDyve Pubget Overpricing